This new paper highlights our analyses on:
- France’s attractiveness for pharma companies
- The implications of the 2026 Social Security Financing Act
- The National Health Insurance deficit and its projected evolution
- An assessment of the profitability of pharma companies operating in France
- The market (in gross and net value) by segment (retail and hospital) and its 2030 perspective
